Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study

• Published in: Eye (London) Vol. 36; no. 4; pp. 716 - 723
• Main Authors: Iovino, Claudio, Peiretti, Enrico, Tatti, Filippo, Querques, Giuseppe, Borrelli, Enrico, Sacconi, Riccardo, Chhablani, Jay, Agrawal, Hitesh, Boon, Camiel J. F., van Dijk, Elon H. C., Cennamo, Gilda, Lupidi, Marco, Muzi, Alessio, Di Iorio, Valentina, Iglicki, Matias, Smadar, Lital, Loewenstein, Anat, Zur, Dinah
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2022; Nature Publishing Group
• Subjects: 692/308/409; 692/699/3161/3175; Acuity; Eye; Fluorescein Angiography; Humans; Laboratory Medicine; Medicine; Medicine & Public Health; Ophthalmology; Patients; Pharmaceutical Sciences/Technology; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - therapeutic use; Pilot Projects; Porphyrins; Prospective Studies; Retrospective Studies; Success; Surgery; Surgical Oncology; Tomography, Optical Coherence; Treatment Outcome; Verteporfin - therapeutic use; Visual Acuity
• DOI: 10.1038/s41433-021-01515-z
• ISSN: 0950-222X

Background To investigate the anatomical and functional results in eyes with peripapillary pachychoroid syndrome (PPS) undergoing photodynamic therapy (PDT). Methods A total of 25 eyes from 23 patients with PPS treated with PDT were retrospectively evaluated in this multicentric study. Main outcome measure was the proportion of eyes that achieved treatment success, defined as a decrease in both subretinal fluid (SRF) height and central subfield thickness (CST), at 3 months after PDT compared to baseline. Secondary outcomes were the change in CST, SRF, and best-corrected visual acuity (BCVA) 3 months after treatment and predictive factors for treatment success. When available, data between 3 and 12 months were also reviewed. Results Treatment success was achieved in 16 eyes (64%). In the total cohort, CST decreased significantly from 356 ± 118 µm at baseline to 282 ± 90 µm and 270 ± 91 µm at 1 and 3 months, respectively ( p  < 0.001). Maximal SRF height decreased significantly from 102 ± 83 µm at baseline to 38 ± 46 µm and 32 ± 42 µm at 1 and 3 months, respectively ( p  < 0.001), and remained stable at month 6 (29 ± 44 µm) and month 12 (23 ± 35 µm). BCVA improved significantly from baseline to month 3 ( p  = 0.021). Conclusions PDT can be considered an efficacious treatment option in patients with PPS. Prospective data with longer follow-up in a bigger cohort are needed in order to determine the optimal treatment algorithm in this relatively novel disease.